GlassScriptPhysician profile
Bilal Ashraf
NPI 1477180685
$952.09
in general payments reported to CMS, 2019-2025
13 companies · $816 in 2025
The $816 reported for 2025 was more than what 86% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $34.44 · 2023: $32.96 · 2024: $68.48 · 2025: $816.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $918.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $917.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Madrigal Pharmaceuticals | $163.72 | 2025 | Rezdiffra |
| Conmed Corporation | $153.46 | 2025 | Conmed Generators, Conmed Dilation |
| Abbvie INC. | $124.40 | 2025 | |
| Regeneron Healthcare Solutions, INC. | $119.53 | 2025 | Dupixent |
| Novo Nordisk INC | $114.39 | 2025 | Wegovy |
| Gilead Sciences, INC. | $94.33 | 2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $47.06 | 2023-2025 | Gattex, Eohilia |
| Merz Pharmaceuticals, LLC | $32.28 | 2025 | Ampyra, Inbrija |
| Genzyme Corporation | $29.27 | 2024 | |
| Ardelyx, INC. | $23.22 | 2024 | Ibsrela |
| Lilly USA, LLC | $18.06 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $16.38 | 2021 | |
| Celltrion USA INC. | $15.99 | 2024 | Vegzelma |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bilal Ashraf listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.